Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹224 Cr
verified against source
Revenue YoY
20%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Thyrocare delivered a strong Q4 FY26 with consolidated revenue of ₹224 crore (+20% YoY) and PAT of ₹48.7 crore (+128% YoY), driven by 21% growth in franchisee business and 23% in partnerships. Test volumes surged 29% YoY due to aggressive biochemistry pricing, while gross margins expanded 113bps to 74.7% from vendor negotiations. Management guided for mid-to-high teens revenue growth in FY27, with 75% from volume and 25% from mix, and expects EBITDA margins to remain stable around 32-34% as operating leverage is reinvested into specialty expansion (genomics, allergy). Key risk: potential reagent price increases from dollar strength could pressure margins if not passed on.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects revenue growth of mid-to-high teens, driven primarily by volume (75%) and mix (25%), with no price increases planned.
- Normalized EBITDA margin expected to remain stable at ~34% as operating leverage is reinvested into growth initiatives.
- Management targets adding approximately 500 net new franchises each quarter, consistent with current run rate.
- Management aims to increase specialty testing (genomics, allergy) to 15-20% of revenue within three years, from a low base.
Risks flagged
- Vendors have requested price increases due to dollar appreciation; if sustained, margins could be pressured unless passed on.
- Q4 partnership growth slowed to 23% due to normalization of insurance pricing and lower camp volumes; management attributes it to a one-off but it may recur.
- Tanzania operations have not yet broken even after 18 months, with quarterly losses of ~₹1 crore, though minimal.
- Investments in specialty (genomics, allergy) will have lower gross margins initially, potentially weighing on overall profitability until scale is achieved.
Key quotes
- We have no intention at this point in time to increase prices.
- Our strategy remains to be the most affordable good quality diagnostic testing partner for anyone in the healthcare business.
- Any operating leverage that comes out of the business is what we invest in growth.
Research modules